

Does your library subscribe to *Molecular Interventions*?



- Scientifically rigorous
- Cutting-edge content
- *MI* keeps you up to date in all areas related to pharmacology
- Professionally designed graphics are perfect for classroom use
- EVERYONE should be reading *MI*!

ASK YOUR LIBRARY TO SUBSCRIBE TODAY!

**No price increase for 2011:
Institutional Online-Only Subscriptions
are just \$268**

molinterv.aspetjournals.org



Postdocs

ASPET Has a Membership Level Just for You



All the benefits of ASPET membership at half the regular membership dues – only \$70

Any qualified person who has received a Ph.D. or equivalent degree in pharmacology or a related field within the past 5 years is eligible for Postdoctoral Membership

Postdoctoral Membership good for up to 5 years after receiving a PhD or equivalent degree

Postdoctoral ASPET Members receive the same benefits as Regular ASPET Members

ASPET membership provides discounts and other advantages

Postdoctoral Members must be sponsored by a Regular or Retired ASPET Member

Apply online at aspet.org

Join today!



**University of California, Davis
Department of Pharmacology**

The University of California, Davis, School of Medicine, Department of Pharmacology invites applications for two full time academic positions (split 50% regular tenure track series and 50% in-residence series) at the Assistant/Associate Professor level. <http://www.ucdmc.ucdavis.edu/pharmacology>. The Pharmacology Department is housed in the UC Davis Genome Center with a new Department Chair, Dr. Donald M. Bers, Ph.D. **The Department has strong links to the Cardiovascular Research Program, Genome Center, Center for Neuroscience, Physiology and Membrane Biology, Biomedical Engineering and UC Davis Health System Cancer Center.**

Candidates must possess a Ph.D. and/or M.D. degree and at least two years of productive postdoctoral experience. Individuals selected for these positions will be expected to build or continue a successful, independent, extramurally funded research program and to achieve excellence in the teaching of basic sciences to medical and graduate students. **The most important criteria in the consideration of applications are: 1) a record of excellence, creativity, and initiative in research, which establishes a strong potential to build a vigorous and competitive research program; and 2) a demonstrated ability to communicate effectively as a teacher.** Applicants for these positions should have research experience and plans that focus on the regulation of plasma membrane ion transporters (e.g. Na/K-ATPase) and/or protein kinase signaling in cardiac hypertrophy. **Strong experience in fluorescence microscopy is essential and should be complemented by either strength in molecular biology or patch clamp.**

The Davis campus is the third largest in the University of California system and ranks among the nation's top 20 universities in research funding. Applicants should send a CV, up to three key reprints, synopsis of research plans, and a summary of teaching experience and should arrange for three to five letters of reference to be sent to: **Donald M. Bers, Ph.D., Silva Chair for Cardiovascular Research and Distinguished Professor & Chair, Department of Pharmacology, 3502 GBSF, University of California, Davis, CA 95616** via e-mail to Linda Petty: lapetty@ucdavis.edu. For full consideration, applications should be received by **October 30, 2010. However, the position will remain open until filled through June 30, 2012.**

The University of California, Davis is an affirmative action/equal opportunity employer with a strong institutional commitment to the achievement of diversity among its faculty, staff, and students

Statement of Ownership, Management, and Circulation (All Periodicals Publications Except Requester Publications)

1. Publication Title: Molecular Pharmacology. 2. Publication Number: 0026-895X. 3. Filing Date: September 1, 2010. 4. Issue Frequency: Monthly. 5. Number of Issues Published Annually: 12. 6. Annual Subscription Price: \$707.00. 7. Complete Mailing Address of Known Office of Publication: American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995; contact person: Richard Dodenhoff; telephone: 301-634-7997. 8. Complete Mailing Address of Headquarters of General Business Office of Publisher: American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995. 9. Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor: Publisher: American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995. Editor: Dr. P. Jeffrey Conn, Vanderbilt University, Department of Pharmacology, 6600 23rd Ave. South at Pierce, Nashville, TN 37232. Managing Editor: Jill Filler, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995. 10. Owner: American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20814-3995. 11. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or Other Securities: None. 12. Tax Status: The purpose, function, and nonprofit status of this organization and the exempt status for federal income tax purposes: Has Not Changed During Preceding 12 months. 13. Publication Title: Molecular Pharmacology. 14. Issue Date for Circulation Data: September 2010. 15. Extent and Nature of Circulation: Average No. Copies Each Issue During Preceding 12 Months: (a) Total Number of Copies (Net press run): 571. (b) Paid Circulation: (1) Mailed Outside-County Paid Subscriptions Stated on PS Form 3541: 281. (2) Mailed In-County Paid Subscriptions Stated on PS Form 3541: 0. (3) Paid Distribution Outside the Mails Including Sales Through Dealers and Carriers, Street Vendors, Counter Sales, and Other Paid Distribution Outside USPS®: 127. (4) Paid Distribution by Other Classes of Mail Through the USPS (e.g. First-Class Mail®): 0. (c) Total Paid Distribution (Sum of 15b. (1), (2), (3), and (4)): 408. (d) Free or Nominal Rate Distribution (By Mail and Outside the Mail): (1) Free or Nominal Rate Outside-County Copies Included on PS Form 3541: 24. (2) Free or Nominal Rate In-County Copies Included on PS Form 3541: 0. (3) Free or Nominal Rate Copies Mailed at Other Classes Through the USPS (e.g. First-Class Mail): 0. (4) Free or Nominal Rate Distribution Outside the Mail: 5. (e) Total Free or Nominal Rate Distribution: 29. (f) Total Distribution: 438. (g) Copies not Distributed: 134. (h) Total: 571. (i) Percent Paid: 93.3333. No. Copies of Single Issue Published Nearest to Filing Date: (a) Total Number of Copies (Net press run): 465. (b) Paid Circulation: (1) Mailed Outside-County Paid Subscriptions Stated on PS Form 3541: 257. (2) Mailed In-County Paid Subscriptions Stated on PS Form 3541: 0. (3) Paid Distribution Outside the Mails Including Sales Through Dealers and Carriers, Street Vendors, Counter Sales, and Other Paid Distribution Outside USPS®: 122. (4) Paid Distribution by Other Classes of Mail Through the USPS (e.g. First-Class Mail®): 0. (c) Total Paid Distribution: 379. (d) Free or Nominal Rate Distribution: (1) Free or Nominal Rate Outside-County Copies Included on PS Form 3541: 29. (2) Free or Nominal Rate In-County Copies Included on PS Form 3541: 0. (3) Free or Nominal Rate Copies Mailed at Other Classes Through the USPS (e.g. First-Class Mail): 0. (4) Free or Nominal Rate Distribution Outside the Mail: 5. (e) Total Free or Nominal Rate Distribution: 34. (f) Total Distribution: 413. (g) Copies not Distributed: 52. (h) Total: 465. (i) Percent Paid: 91.7676. 16. Publication of Statement of Ownership: Publication required. Will be printed in the October 2010 issue of this publication. 17. I certify that all information furnished on this form is true and complete. I understand that anyone who furnishes false or misleading information on this form or who omits material or information requested on the form may be subject to criminal sanctions (including fines and imprisonment) and/or civil sanctions (including civil penalties). Richard Dodenhoff, Journals Director, August 31, 2010.